Asset
EMPASIPRUBART
ARGENX SE AMERICAN DEPOSITARY SHARES
Revenue
No revenue reported in loaded filings.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05405361 | phase2 | active_not_recruiting | 2023-01-18 | 2029-09-30 | argenx | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT05225675 | phase2 | completed | 2022-03-31 | 2024-06-04 | argenx | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT06920004 | phase3 | recruiting | 2025-08-22 | 2027-09-01 | argenx | A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP |
| NCT06742190 | phase3 | active_not_recruiting | 2024-12-18 | 2026-09-01 | argenx | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy |
| NCT05907096 | phase2 | active_not_recruiting | 2024-02-17 | 2025-10-16 | argenx | ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function |
FDA applications (0)
This company has no applications containing this asset.